Further investigation showed that BsAb could strongly inhibit inflammatory factor production in vivo compared with control mice, including IL-6, although TNF-α was not reduced by BsAb, which may alleviate chronic inflammation during the progress of tumor treatment. Here, IL6 is linked to neoplasm.